“One faster and more than four” Yantai Biopharmaceutical Silicon Valley is just around the corner

In the cultivation of biomedical industry, Yantai Development Zone insists on putting talents in a strategic position of priority development, launching a package of high-gold support policies in terms of talents, projects, platforms, intellectual property rights, financing, etc., and vigorously introducing “Thousand Talents Plan”. First-class talents at home and abroad and innovative teams led by academicians and doctors. Dr. Fang Jianmin was introduced to cooperate with Tongji University and Rongchang Pharmaceutical to establish a joint platform and development base for bio-new drug creation, and developed a new class of drugs in 8 countries. RC48 became the first target cancer treatment drug in the country.

In Shanghai, he is a professor at the School of Life Science and Technology of Tongji University and the director of the Molecular Medicine Laboratory. In Yantai, he is the co-founder and chief scientist of Rongchang Biopharmaceutical (Yantai) Co., Ltd. and also a Maibray International Biomedical Co., Ltd. Chairman of the board. At the same time, as a member of the overall expert group of major scientific and technological special projects for the “Major New Drug Creation” during the “Twelfth Five-Year Plan” period, he often went to Beijing to participate in the national major project, review and inspection of direct participation in new drug projects. Since returning to China, Fang Jianmin is most proud of his own creation of a complete set of biopharmaceutical drug development and transformation innovation system from the source to find the reagent bottle to the large-scale production of beds.

In his system, from the perspective of industrial manufacturing, Maibri has been able to provide one-stop outsourcing services for the development of international standards for biopharmaceuticals to GMP production, and to help the innovative ecology of new drug research and development in China; from the perspective of product development, Rongchang Bio is a clinical trial of a new class of new drugs in many countries; from a basic research perspective, he leads his team to constantly search for new therapies in the unknown areas of biomedicine.

Fang Jianmin is only a member of the biomedical think tank of Yantai Development Zone. Through the vigorous implementation of “talent + platform”, “talent + project” and “talent + industry”, the bio-pharmaceutical industry in Yantai Development Zone has quickly become the most concentrated industry for high-end talents.

Yantai Development Zone has planned a bio-pharmaceutical industrial park covering an area of ​​2 square kilometers, taking into account the supporting policies such as industrial development orientation, spatial layout and supporting support, and successively arranged Rongchang Biomedical Park, Proji Biomedical Park and Dongcheng Pharmaceutical Biotechnology. Special parks such as the Medical Park and the New Era Health Industrial Park have given special support in terms of talent introduction, project construction, and scientific and technological innovation, accelerating the process of industrial scale, and gradually forming a pattern of interaction, dislocation competition, and cluster development of large and small parks.

Looking at the bio-pharmaceutical industry in Yantai Development Zone, the development trend of “one faster than four” is presented. “One quick” means that the development momentum is rapid and fast. The average annual growth rate of “12th Five-Year” output value has reached 25%, from 4.23 billion yuan in 2010 to 13.12 billion yuan in 2015, 2016. The output value has reached more than 16 billion yuan, and the final output value of the "13th Five-Year Plan" is expected to exceed 40 billion yuan, becoming an important biological "medical valley" in northern China.

“Four more”, that is, “a large number of enterprises”: There are 103 biomedical and health care products companies in the district, including 13 above-scale, covering biopharmaceuticals, medical devices, diagnostic reagents and vaccines, modern Chinese medicines, bio-health products, etc. In the field; “high-end products are more”: 30 kinds of new drugs have been approved and under research, and 31 national third-class medical devices (the highest level), with 21 domestic first-class, international leading innovations and products, effective The invention patents reached 153, and it is leading domestically in the fields of antibody drugs, recombinant protein drugs, peptide drugs, etc. Biofilm, skin repair film, bone repair materials, nerve repair new materials and other products have strong competitive advantages in China; More talents: gathered world-class leading talents such as Luo Yongzhang, Fang Jianmin, Wang Aijun, 8 experts with “Thousand Talents Program”, 13 “Taishan Scholars” and 22 Ph.D. R&D teams, engaged in research and development of biomedical health industry. More than 2,700 people; "more technology platforms": set up a national engineering laboratory for anti-tumor protein drugs, national innovative drug incubation , The bio-tech industry base in Shandong Province and other innovative platform above the level of high-end innovation incubator support, engineering laboratories, engineering technology centers, enterprise technical centers reached 36, of which more than 26 provincial innovation platform.

In the cultivation of biomedical industry, Yantai Development Zone insists on putting talents in a strategic position of priority development, launching a package of high-gold support policies in terms of talents, projects, platforms, intellectual property rights, financing, etc., and vigorously introducing “Thousand Talents Plan”. First-class talents at home and abroad, and innovative teams led by academicians and doctors, set high-end creative spaces such as China-Europe Business Entrepreneurship Park and Yida Chuangke Space, and build a support structure with high-end talents as the core.

Dr. Fang Jianmin was introduced to cooperate with Tongji University and Rongchang Pharmaceutical to establish a joint platform and development base for bio-new drug creation, and developed a new class of drugs in 8 countries. RC48 became the first target cancer treatment drug in the country, Maibray The company's antibody drug outsourcing technology is the first in China, and the large-scale production of ADC drugs is the first in Asia. Dr. Luo Yongzhang led the founding of Progi Bio and Proji Medicine, and developed the world's first tumor detection product approved by heat shock protein 90α as a marker. It was listed as the “Twelfth Five-Year National Basic Research” by the Ministry of Science and Technology. One of the major world frontier achievements. Sun Wei, Chairman of the International Bio-Industrial Association, and Lutong Precision have set up Shangruiyuan Biotechnology to carry out bio-3D printing equipment and human body tissue and organ industrialization research and development, with broad application prospects and good social benefits.

At present, the Yantai Development Zone has started the construction of the Biomedical Innovation Incubation Center. The Chinese Academy of Sciences and the Academician of the Chinese Academy of Sciences have served as the first chairman of the Board of Directors to build a domestic first-class biomedical R&D and production base. Yantai Biopharmaceutical Silicon Valley is just around the corner.

Ph Test Kit Soil

Ph Test Kit Soil,Soil Ph Test Strips,Soil Ph Test Paper,Best Soil Ph Test Kit

Changchun LYZ Technology Co., Ltd , https://www.lyzinstruments.com